Workshop II: "neuroprotection"--the Lugano consensus.
J Neurol
; 247 Suppl 4: IV/36-7, 2000 Sep.
Article
em En
| MEDLINE
| ID: mdl-11199817
ABSTRACT
Consensus could be reached that there is overwhelming evidence of preclinical neuroprotection. However, the evidence of neuroprotection/neurorescue under clinical conditions is limited. Lessons from clinical trials designed to show neuroprotection (selegiline, amantadine, dopamine agonists) demonstrate that with the drugs available neuroprotection/neurorescue has to start as early as possible. A PET-controlled clinical trial with ropinirole shows that there seems to be a good chance for neuroprotection in the early phase of Parkinson's disease in patients treated from the very beginning of the disease while there is no such benefit in patients with a late start of a neuroprotective therapeutic strategy. Also long-term neuroprotection cannot be reached. Complicating factors to demonstrate clinical neuroprotection are discussed.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Doença de Parkinson
/
Dopaminérgicos
/
Fármacos Neuroprotetores
/
Degeneração Neural
Idioma:
En
Ano de publicação:
2000
Tipo de documento:
Article